GLP-1 agonists shine in diabetes combination therapy, study shows

But sulfonylureas should be avoided as second-line therapy, the researchers say

Adding a GLP-1 agonist to other diabetes drugs reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality, a population-based study suggests.